Cornea

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

According to the organization, the goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness.

Corneal collagen crosslinking was found to stabilise the cornea, and in some cases improve vision and keratometry values, in children and young adults.

Although graft rejection has not been associated with vaccinations, concern remains.

Impairment of corneal sensory innervation causes reduction of both protective reflexes and trophic neuromodulators that are essential for the vitality, metabolism, and wound healing of the ocular surface.

According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.

TearLab Corp. announced that Adam Szaronos has been appointed president and CEO by the company's Board of Directors, effective immediately.

Investigators are hopeful that future research can focus on public health concerns of dry eye disease.

The company will begin commercialization of the IC-8 small aperture IOL, used for cataract patients, upon successful completion of the manufacturing facility inspections and receipt of an official approval order from the FDA, which the company estimates in Q2 2022.

Study shows statistically significant improvement for primary endpoint of bulbar conjunctival hyperemia for OTX-DED 0.2 mg and 0.3 mg formulations compared with vehicle hydrogel insert.

Successful treatment options can offer hope for patients with inherited disease.

Approaches include anti-vascular endothelial growth factor agents, fine needle diathermy, and corneal collagen crosslinking.

New acrylic implant provides option for patients with endothelial dysfunction.

In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall pointed out that an epidemiologic analysis of malignant ocular surface tumours found significant differences in geographic prevalence rates in the United States.

Shady Awwad, MD, discusses how the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.

Dr Shady Awwad in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and instead contributes to development of more corneal haze.

Procedure transfers intact donor nerve fibers to the cornea.

New serological biomarkers could characterise Sjögren’s syndrome better than traditionally used autoantibodies.

Results from Aurion Biotech's IOTA trial reveals that a corneal endothelial cell therapy showed improvements in visual acuity and central corneal thickness, according to a team of Japanese investigators.

Cynthia Matossian, MD, FACS, ABES, takes a look at the recent, sudden change in low-payment reimbursement by Medicare Administrative Contractors for LipFlow and MGD procedure codes.

Investigators sought to develop a severity scale for tomographic edema in FECD based on Scheimpflug tomography maps, and to evaluate intra- and inter-observer variation for assessing severity.

A cross sectional study investigated how chronic pain conditions outside of the eye impact corneal sensitivity.

A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.